Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

33.05
-0.2150-0.65%
Volume:1K
Turnover:38.54K
Market Cap:6.61M
PE:- -
High:33.15
Open:33.15
Low:33.05
Close:33.27
52wk High:43.01
52wk Low:26.17
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.02
T/O Rate:0.58%
Dividend:0.32
Dividend Rate:0.96%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
Sep 12

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS
·
Sep 12

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Sep 12

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
Sep 12

US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older

THOMSON REUTERS
·
Sep 12

Scholar Rock Holdings trading halted, news pending

TIPRANKS
·
Sep 12

NASDAQ Trade Halt Halt News Pending at 05:07 Pm

Reuters
·
Sep 12